News | Heart Failure | June 30, 2016

Researchers Discover New Pathway to Treat Heart Failure

Team at Thomas Jefferson University discovers a new way to keep the heart pumping, which could lead to new drugs for heart disease

beta-blockers, Thomas Jefferson University, beta-adrenergic receptors

Selective activation of the beta2-adrenergic receptor (beta2AR) by a beta-arrestin-biased pepducin promotes activation of a beta-arrestin signaling pathway that is cardioprotective. Image courtesy of the lab of Jeffrey Benovic, Thomas Jefferson University.

June 30, 2016 — Researchers at Thomas Jefferson University have discovered how to enhance the effectiveness of beta-blockers for heart failure patients by tapping an alternate pathway that both blocks damage to the heart and helps it keep pumping. The research, published online in the Proceedings of the National Academy of Sciences (PNAS), offers the possibility of developing a new and potentially more effective class of heart-failure medications.

About 5.7 million Americans have heart failure, half of whom will die from the disease within five years, according to the Centers for Disease Control and Prevention (CDC). Two processes help drive the disease: a weakened heart muscle that is less able to pump, and the death of heart cells that irreparably damage the heart. Beta-blockers, commonly used to treat heart disease, work by blocking the beta-adrenergic receptors in the heart, saving heart cells from cell death. But beta-adrenergic receptors also help keep the heart pumping, a function that this medication also blocks.

 “There’s much more work to be done before this is ready for patients, but this is an excellent example of how a little curiosity in the basic research laboratory can lead to discoveries that have the potential to change the way we treat a very common and very deadly illness,” said senior author Jeffrey Benovic, Ph.D., Thomas Eakins Professor and chair of the Department of Biochemistry and Molecular Biology at the Sidney Kimmel Medical College and associate director at the Sidney Kimmel Cancer Center at Thomas Jefferson University.

Of the beta-adrenergic receptors present in the heart, it is the beta1-adrenergic receptors that are primarily responsible for the heart’s contraction, or pumping action, and that are targeted by traditional beta-blockers. Benovic’s lab, however, had developed a series of molecules called pepducins that were derived from pieces of the beta2-adrenergic receptor, and which, they discovered, could selectively activate the very receptor they came from.

It was while former graduate student Richard Carr, in Benovic’s lab, was characterizing the properties of these pepducins that he noticed that the molecule shared similar characteristics to a common heart-failure medication called carvedilol. They sent the pepducin to their colleague Douglas Tilley, Ph.D., at Temple University who tested how heart cells responded to the molecule. “He was blown away by what he saw,” said Benovic.

When Tilley pulsed the heart cells with the pepducin, the cells started to beat more forcefully. “We didn’t expect that this would happen,” said Benovic. The pepducin they were using was specific for the beta2-adrenergic receptor pathway, and didn’t have any effect on the beta1 receptors. The researchers had demonstrated for the first time that contraction of heart muscle cells could be triggered via the beta2-adrenergic receptor, using this novel pepducin.

Through further biochemical analysis the researchers showed that the pepducin activated the ability of the beta2-adrenergic receptor to interact with a secondary signaling molecule called beta-arrestin, and that it was this interaction that promoted the heart cells to beat. In addition, the pepducin only activated the beta2 receptor to 40 or 50 percent. By tinkering with the pepducin molecules, said Benovic, “we think we can get full activation.”

The next steps, said Benovic, are to design a better version of the pepducin. In addition, Benovic and colleagues plan to screen existing small molecules, or drugs, to see if one can mimic the action of the pepducin. They also plan to study the structure of the pepducin and the beta2 receptors to gain better insight into the design of more effective pepducin-like molecules.

“If we find or design a compound that works like this pepducin, it wouldn’t necessarily cure heart disease, but it would give doctors another tool to help bolster a failing heart,” said Benovic.

This research was supported by National Institutes of Health awards R37 GM047417, R01 GM068857, P01 HL114471, R01 HL105414, RO1 HL074854, P01 HL075443, P01 HL091799 and T32 GM100836. The authors report no conflicts of interest.

For more information: www.pnas.org

Related Content

Guideline Adherence, Not Patient Volume, May Be Better Hospital Heart Failure Metric
News | Heart Failure | February 01, 2018
February 1, 2018 –  In evaluating the quality of care given to those hospitalized with...
First-in-Man RenalGuard Studies Show Promise for Heart Failure Patients
News | Heart Failure | January 02, 2018
RenalGuard Solutions Inc. reported positive results from a first-in-man feasibility study focusing on a novel use of...
ACC Issues New Guidance to Optimize Heart Failure Treatment
News | Heart Failure | December 22, 2017
December 22, 2017 — To help streamline treatment of patients with...
Coffee Associated With Reduced Risk of Heart Failure, Stroke. AHA 2017. #AHA2017
News | Heart Failure | November 25, 2017
November 25, 2017 — Drinking coffee may be associated with a decreased risk of developing heart failure or having str
Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years among U.S. veterans, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions.
News | Heart Failure | November 25, 2017
November 25, 2017 — Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years a
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure | November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure | November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Heart Failure | November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure | October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure | October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Overlay Init